Summit Therapeutics plc Summit Therapeutics Plc : Holding(s) In Company
25 January 2017 - 11:45PM
UK Regulatory
TIDMSUMM
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
1. Identity of the issuer or the underlying issuer SUMMIT THERAPEUTICS PLC
of existing shares to which voting rights are
attached: (ii)
2 Reason for the notification (please tick the appropriate
box or boxes):
An acquisition or disposal of voting rights x
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition of
shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar
economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the ROBERT KEITH
notification obligation: (iii)
4. Full name of shareholder(s)
(if different from 3.):(iv)
5. Date of the transaction and date on 20 JANUARY 2017
which the threshold is crossed or
reached: (v)
6. Date on which issuer notified: 25 JANUARY 2017
7. Threshold(s) that is/are crossed or BELOW 8%, 7%
reached: (vi, vii)
8. Notified details:
A: Voting rights attached to shares (viii, ix)
Class/type of
shares Situation previous
if possible using to the triggering
the ISIN CODE transaction Resulting situation after the triggering transaction
Number
Number of
of Voting Number Number of voting
Shares Rights of shares rights % of voting rights (x)
Direct Direct (xi) Indirect (xii) Direct Indirect
GB00B8DX2616 4,040,610 4,040,610 3,040,610 3,040,610 4.9%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Number of voting
rights that may be
acquired if the
Type of financial Expiration Exercise/ instrument is % of voting
instrument date (xiii) Conversion Period (xiv) exercised/ converted. rights
AMERICAN DEPOSITORY SHARES
(ADS) N/A N/A 1,164,700 1.88%
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
Resulting situation after the triggering transaction
Type of financial Expiration Exercise/ Conversion
instrument Exercise price date (xvii) period (xviii) Number of voting rights instrument refers to % of voting rights (xix, xx)
Spreadbet 89,506 Nominal Delta
.14%
Total (A+B+C)
Number of voting rights Percentage of voting rights
4,294,816 6.92%
9. Chain of controlled undertakings through which
the voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease
to hold:
12. Date on which proxy holder will cease to hold
voting rights:
13. Additional information:
14. Contact name: JOCELYN M. BENNETT
15. Contact telephone number: +41 22 809 9500
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
January 25, 2017 07:45 ET (12:45 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Ther News Articles